El-Khoueiry, A. B., Balli, D., Blanc, J., Rosmorduc, O., Decaens, T., Mathurin, P., Merle, P., Dayyani, F., Masi, G., Pressiani, T., Galle, P. R., Hatogai, K., Mueller, U., Kalambakas, S. A., Weispfenning, A., Ishii, Y., Bouattour, M. (2025). Expanded biomarker analysis of an international, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.635